---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002001"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T01:08:48.440892+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO

## Summary
- Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.
- Phase 2 THIO-101 expansion underway; potential accelerated approval filing in 2026.
- Phase 3 THIO-104 set to begin mid-2025; potential full approval filing in 2026.
- Multiple THIO trials planned in additional cancer indications.
- Significant market opportunity in hard-to-treat cancers with unmet medical needs.

## SEC filing metadata
- accession: 0001641172-25-002001
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225002001/0001641172-25-002001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225002001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002001
- JSON: https://secwatch.observer/filing/0001641172-25-002001.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.